Simulations Plus Releases GastroPlus™ Version 9.6

Keywords: Advanced Compartmental Absorption Transit (ACAT) model, drug-drug interactions (DDIs), in vitro-in vivo correlations (IVIVCs), oral absorption, PBPK modeling, U.S. FDA
Software: GastroPlus®
Division: PBPK

Simulations Plus, Inc. (NASDAQ: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 9.6 of its flagship PBPK modeling program, GastroPlus™.

Key improvements include:

  • New dynamic intestinal fluid options added to the #1-ranked ACAT™ oral absorption model
  • New population physiologies for obesity and renal impairment disease states
  • Expanded enzyme/transporter distribution information for easier extrapolation across species
  • Additional compound model files for standard drug-drug interaction (DDI) substrates and inhibitors
  • Upgraded capabilities to all major mechanistic absorption routes, including dermal, pulmonary, ocular, and subcutaneous/intramuscular injections
  • Enhanced deconvolution methods for generation of mechanistic in vitro-in vivo correlations (IVIVCs)
  • Improved output/reporting functions in all simulation modes to facilitate communication across departments and with regulatory agencies
  • Significant simulation speed improvements
  • Custom template generation for seamless use of GastroPlus to drive DILIsym® SimPops™ liver injury predictions
  • And more…

Dr. Viera Lukacova , director – simulation sciences, said: “This version of GastroPlus provides new features that users have requested and will appreciate. It is the product of ongoing input and collaboration with the U.S. FDA, industry, academics, and by our talented Simulations Plus and DILIsym® Services scientific teams.”

John DiBella , president – Lancaster division, added: “GastroPlus continues to be the mostly widely used commercial PBPK software worldwide, and this new release is the most feature-rich and user-friendly in our history. With the ever-increasing emphasis on PBPK modeling from regulatory agencies globally, the client base for GastroPlus continues to expand. For over 20 years, our company has invested to improve our software tools and attract the most talented scientists, and this will continue as we look to meet the unprecedented demand for PBPK modeling support and new functionality requests.”